News

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity

AT&T's (NYSE: T) stock turnaround has been one of the more surprising happenings in the stock market over the past 12 months. Its stock is up by around 52% in that span and has nearly touched its

Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps

Volatility has returned to the stock market. In particular, the tech-heavy Nasdaq Composite has suffered a rough start to the year. As of this writing, the index has dropped about 3.8% year to date

Shares of veteran telecom company AT&T (NYSE: T) saw a resurgence in recent months. The stock hit a 52-week high of $27.97 on March 4, the highest it's been in years, and is up more than 50% over

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Though the drugmaker had performed well since the beginning of the decade, it encountered issues that sank

Teleflex's (NYSE: TFX) fourth-quarter 2024 earnings conference call, held on February 27, 2025, revealed significant strategic shifts for the medical device company. In a transformative

It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked three Motley Fool contributors to pick slam-dunk growth stocks investors

Chipsets known as graphics processing units (GPUs) are perhaps the most important hardware in generative AI development right now. For the last couple of years, investing in semiconductor stocks has

What makes an outstanding dividend stock? High yields can seem attractive to income seekers, but unless a company has a steady, reliable business, payout cuts are a real possibility no matter how

The average tax refund in 2024 was $3,138, which was similar to the $3,167 it averaged the previous year. While tax refunds will vary depending on a person's individual financial situation, if you

Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation maintains its dividend program, the more attractive it is to income seekers

Finding stocks that will outperform the market is no easy task. Indeed, according to First Trust advisors, only 28% of stocks outperformed the S&P 500 in 2024.

That said, it's not impossible to

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. However, even in a bull market, like the one we're currently

The technology-heavy Nasdaq Composite (NASDAQINDEX: ^IXIC) has tumbled 3% year to date, and that slight decline has created some no-brainer buying opportunities. The market reacted too

Late last year, Morgan Stanley issued a forecast suggesting Amazon, Microsoft, Alphabet, and Meta Platforms could spend a combined $300 billion on data center infrastructure and chips to power their

In this video, Motley Fool contributor Jason Hall explains why AT&T (NYSE: T), after a great 19 month run, isn't likely to outperform the market going forward.

*Stock prices used were from the

Buying low to sell later when the stock's price is high is a time-honored investing strategy. With the benchmark S&P 500 index near its all-time high, though, now might seem like the wrong time to

It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges.

However, three Motley Fool contributors think they can make the

The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype around weight loss drugs isn't new, but when people are losing more than